Jennifer M. Johnson

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe et al. · The Lancet Oncology · 2022 · 225 citations · Full text

Medicine, Previous Pd, Bronchial Neoplasm +5

Absence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia

David W. Miller, Jennifer M. Johnson, Steven M. Solano et al. · Journal of Neural Transmission · 2005 · 201 citations

Neurodegenerative Diseases, Molecular Neuroscience, Synaptic Signaling +10

Phase 1/2a, open‐label, multicenter study of <scp>RM</scp>‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma

David M. Cognetti, Jennifer M. Johnson, Joseph Curry et al. · Head & Neck · 2021 · 157 citations · Full text

Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies

Jeffrey S. Ross, Laurie M. Gay, K. Wang et al. · Annals of Oncology · 2017 · 109 citations · Full text

Insurance-mandated preoperative dietary counseling does not improve outcome and increases dropout rates in patients considering gastric bypass surgery for morbid obesity

Mohammed Jamal, Eric J. DeMaria, Jennifer M. Johnson et al. · Surgery for Obesity and Related Diseases · 2006 · 102 citations

Obesity, Nutrition, Bariatric Surgery +10